Angelini has been rapped under the UK pharma industry’s code of practice for criticising licensing decisions made by the EMA and other breaches.
Otsuka preps for July decision on centanafadine for ADHD
The FDA has started a priority review of Otsuka’s triple-acting drug for ADHD, setting up a decision on the first-in-class drug in July.

